LTC2076501I2 - 3-[5-(2-fluorfenil)-[1,2,4]oksadiazol-3-il]benzenkarboksirūgšties kristalinės formos - Google Patents

3-[5-(2-fluorfenil)-[1,2,4]oksadiazol-3-il]benzenkarboksirūgšties kristalinės formos

Info

Publication number: LTC2076501I2
Authority: LT; Lithuania
Prior art keywords: oxadiazol; fluorophenyl; benzoic acid; crystalline form; crystalline
Prior art date: 2006-09-25

Application number

LTPA2016012C

Other languages

English (en)

Original Assignee

Ptc Therapeutics, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-25

Filing date

2016-04-22

Publication date

2017-10-10

2016-04-22 Application filed by Ptc Therapeutics, Inc. filed Critical Ptc Therapeutics, Inc.

2017-10-10 Publication of LTC2076501I2 publication Critical patent/LTC2076501I2/lt

Links

OOUGLTULBSNHNF-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(ON=2)C=2C(=CC=CC=2)F)=C1 OOUGLTULBSNHNF-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Tropical Medicine & Parasitology (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Psychology (AREA)

LTPA2016012C 2006-09-25 2016-04-22 3-[5-(2-fluorfenil)-[1,2,4]oksadiazol-3-il]benzenkarboksirūgšties kristalinės formos LTC2076501I2 (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US84732606P	2006-09-25	2006-09-25
PCT/US2007/020633 WO2008039431A2 (en)	2006-09-25	2007-09-24	Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid

Publications (1)

Publication Number	Publication Date
LTC2076501I2 true LTC2076501I2 (lt)	2017-10-10

Family

ID=39123850

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTPA2016012C LTC2076501I2 (lt)	2006-09-25	2016-04-22	3-[5-(2-fluorfenil)-[1,2,4]oksadiazol-3-il]benzenkarboksirūgšties kristalinės formos

Country Status (29)

Country	Link
US (10)	US7863456B2 (lt)
EP (2)	EP2076501B8 (lt)
JP (6)	JP5714228B2 (lt)
KR (1)	KR101430144B1 (lt)
CN (3)	CN104341371A (lt)
AR (2)	AR062963A1 (lt)
AU (1)	AU2007300542B2 (lt)
BR (1)	BRPI0717107A2 (lt)
CA (1)	CA2663574C (lt)
CL (1)	CL2007002743A1 (lt)
DK (1)	DK2076501T3 (lt)
ES (2)	ES2655338T3 (lt)
HK (1)	HK1207070A1 (lt)
HU (1)	HUE028503T2 (lt)
IL (1)	IL197717A (lt)
LT (1)	LTC2076501I2 (lt)
MX (2)	MX344418B (lt)
MY (1)	MY191209A (lt)
NO (1)	NO341858B1 (lt)
NZ (1)	NZ575795A (lt)
PE (3)	PE20151445A1 (lt)
PL (2)	PL2076501T3 (lt)
PT (1)	PT2076501E (lt)
SG (2)	SG185979A1 (lt)
SI (1)	SI2076501T1 (lt)
TW (2)	TWI452038B (lt)
UA (1)	UA99600C2 (lt)
WO (1)	WO2008039431A2 (lt)
ZA (1)	ZA200901949B (lt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE047569T2 (hu)	2003-04-11	2020-04-28	Ptc Therapeutics Inc	1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása
PT2402002T (pt) *	2005-04-08	2018-10-08	Ptc Therapeutics Inc	Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense
RU2462246C2 (ru)	2006-03-30	2012-09-27	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней
PL2076501T3 (pl) *	2006-09-25	2016-06-30	Ptc Therapeutics Inc	Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego
RS54025B1 (sr)	2006-10-12	2015-10-30	Ptc Therapeutics Inc.	Postupci doziranja oralno aktivnog 1,2,4-oksadiazola za supresionu terapiju nonsens mutacije
KR101713453B1 (ko)	2010-03-12	2017-03-07	오메로스 코포레이션	Pde10 억제제 및 관련 조성물 및 방법
WO2014153643A1 (en) *	2013-03-26	2014-10-02	The University Of British Columbia	Compositions and methods for use thereof in the treatment of aniridia
US9347014B2 (en)	2013-04-03	2016-05-24	Gfo Oil Llc	Methods and systems for generating aldehydes from organic seed oils
HUE038169T2 (hu)	2013-09-06	2018-09-28	Aurigene Discovery Tech Ltd	1,2,4-Oxadiazol származékok mint immunomodulátorok
KR102497273B1 (ko)	2014-03-06	2023-02-07	피티씨 테라퓨틱스, 인크.	1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염
NZ716494A (en)	2014-04-28	2017-07-28	Omeros Corp	Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) *	2014-04-28	2016-03-31	Omeros Corp	Optically active pde10 inhibitor
KR101703137B1 (ko)	2014-05-30	2017-02-07	선문대학교 산학협력단	당 부가 아미노글리코사이드 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
CN105461650B (zh) *	2014-09-12	2018-04-13	杭州普晒医药科技有限公司	一种噁二唑化合物的溶剂化物及其制备方法
KR102894264B1 (ko)	2015-03-10	2025-12-02	오리진 온콜로지 리미티드	면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
KR20170139074A (ko)	2015-04-24	2017-12-18	오메로스 코포레이션	Pde10 억제제 및 관련 조성물 및 방법
JP2018531975A (ja)	2015-10-30	2018-11-01	ピーティーシーセラピューティクス，インコーポレーテッド	てんかんの治療方法
WO2017079678A1 (en)	2015-11-04	2017-05-11	Omeros Corporation	Solid state forms of a pde10 inhibitor
EP3442512A4 (en) *	2016-04-15	2020-07-22	The UAB Research Foundation	METHODS AND COMPOUNDS FOR STIMULATING THE TRANSLECTURE OF PREMATURE TERMINATION CODONS
WO2018050706A1 (en) *	2016-09-13	2018-03-22	Marco Cipolli	Method of treatment of shwachman-diamond syndrome
WO2019061324A1 (en) *	2017-09-29	2019-04-04	Curis Inc.	CRYSTALLINE FORMS OF IMMUNOMODULATORS
EP3694841A1 (en)	2017-10-11	2020-08-19	Aurigene Discovery Technologies Limited	Crystalline forms of 3-substituted 1,2,4-oxadiazole
MY206121A (en)	2017-11-03	2024-11-29	Aurigene Discovery Tech Ltd	Dual inhibitors of tim-3 and pd-1 pathways
AU2018360389B2 (en)	2017-11-06	2024-09-19	Aurigene Oncology Limited	Conjoint therapies for immunomodulation
EP3952867A4 (en)	2019-04-10	2023-01-11	PTC Therapeutics, Inc.	METHODS OF TREATMENT OF NONSENSE MUTATION MEDIATED DUCHENNE MUSCULAR DYSTROPHY IN PEDIATRIC PATIENTS
JP7339900B2 (ja) *	2020-02-26	2023-09-06	新井上	視野異常診断方法、視野異常診断装置
KR102665711B1 (ko) *	2021-12-21	2024-05-14	재단법인 아산사회복지재단	Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물
WO2025110781A1 (ko) *	2023-11-24	2025-05-30	재단법인 아산사회복지재단	Ampd3를 포함하는 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 ampd3 저해제를 포함하는 신경섬유종증 예방 또는 치료용 약학 조성물
CN118178408A (zh) *	2024-03-22	2024-06-14	核工业总医院	Ptc124在制备治疗血小板无力症的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW264475B (lt)	1991-09-20	1995-12-01	Takeda Pharm Industry Co Ltd
US6660753B2 (en) *	1999-08-19	2003-12-09	Nps Pharmaceuticals, Inc.	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP2005504014A (ja) *	2001-06-08	2005-02-10	サイトビアインコーポレイテッド	カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された３−アリール−５−アリール−［１，２，４］−オキサジアゾール類および類似体、並びにその使用法
MY151199A (en) *	2001-11-02	2014-04-30	Rigel Pharmaceuticals Inc	Substituted diphenyl heterocycles useful for treating hcv infection
AU2003247610A1 (en) *	2002-06-21	2004-01-06	Ptc Therapeutics, Inc.	METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US8374966B1 (en) *	2002-08-01	2013-02-12	Oracle International Corporation	In memory streaming with disk backup and recovery of messages captured from a database redo stream
TW200424183A (en) *	2002-08-09	2004-11-16	Nps Pharma Inc	New compounds
GB0303503D0 (en) *	2003-02-14	2003-03-19	Novartis Ag	Organic compounds
US7135575B2 (en) *	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
HUE047569T2 (hu) *	2003-04-11	2020-04-28	Ptc Therapeutics Inc	1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása
WO2004110351A2 (en) *	2003-05-14	2004-12-23	Anadys Pharmaceuticals, Inc.	Heterocyclic compounds for treating hepatitis c virus
EP2402323A3 (en) *	2004-10-13	2012-05-30	PTC Therapeutics, Inc.	Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
JP2008523090A (ja) *	2004-12-08	2008-07-03	バイオマリンファーマシューティカルインコーポレイテッド	新生児肺高血圧症の治療のための方法および組成物
PT2402002T (pt)	2005-04-08	2018-10-08	Ptc Therapeutics Inc	Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense
MX2009002439A (es)	2006-09-08	2009-03-27	Ptc Therapeutics Inc	Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos.
PL2076501T3 (pl) *	2006-09-25	2016-06-30	Ptc Therapeutics Inc	Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego
KR102497273B1 (ko) *	2014-03-06	2023-02-07	피티씨 테라퓨틱스, 인크.	1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염

2007
- 2007-09-24 PL PL07838770T patent/PL2076501T3/pl unknown
- 2007-09-24 KR KR1020097008202A patent/KR101430144B1/ko active Active
- 2007-09-24 MX MX2011007120A patent/MX344418B/es unknown
- 2007-09-24 EP EP07838770.1A patent/EP2076501B8/en active Active
- 2007-09-24 SG SG2012082715A patent/SG185979A1/en unknown
- 2007-09-24 SG SG10201609581TA patent/SG10201609581TA/en unknown
- 2007-09-24 HU HUE07838770A patent/HUE028503T2/en unknown
- 2007-09-24 PT PT78387701T patent/PT2076501E/pt unknown
- 2007-09-24 MX MX2009003160A patent/MX2009003160A/es active IP Right Grant
- 2007-09-24 AU AU2007300542A patent/AU2007300542B2/en active Active
- 2007-09-24 CN CN201410561812.3A patent/CN104341371A/zh active Pending
- 2007-09-24 ES ES12185448.3T patent/ES2655338T3/es active Active
- 2007-09-24 UA UAA200904012A patent/UA99600C2/ru unknown
- 2007-09-24 DK DK07838770.1T patent/DK2076501T3/da active
- 2007-09-24 SI SI200731750A patent/SI2076501T1/sl unknown
- 2007-09-24 CN CN201110283329.XA patent/CN102382075B/zh active Active
- 2007-09-24 BR BRPI0717107-2A patent/BRPI0717107A2/pt not_active Application Discontinuation
- 2007-09-24 CL CL200702743A patent/CL2007002743A1/es unknown
- 2007-09-24 MY MYPI20091186A patent/MY191209A/en unknown
- 2007-09-24 JP JP2009529270A patent/JP5714228B2/ja active Active
- 2007-09-24 PL PL12185448T patent/PL2559689T3/pl unknown
- 2007-09-24 US US11/904,005 patent/US7863456B2/en active Active
- 2007-09-24 ZA ZA200901949A patent/ZA200901949B/xx unknown
- 2007-09-24 NZ NZ575795A patent/NZ575795A/en unknown
- 2007-09-24 AR ARP070104212A patent/AR062963A1/es not_active Application Discontinuation
- 2007-09-24 ES ES07838770.1T patent/ES2563958T3/es active Active
- 2007-09-24 EP EP12185448.3A patent/EP2559689B1/en active Active
- 2007-09-24 CA CA2663574A patent/CA2663574C/en active Active
- 2007-09-24 WO PCT/US2007/020633 patent/WO2008039431A2/en not_active Ceased
- 2007-09-24 CN CNA200780043582XA patent/CN101541770A/zh active Pending
- 2007-09-25 PE PE2015001242A patent/PE20151445A1/es not_active Application Discontinuation
- 2007-09-25 PE PE2011001746A patent/PE20120768A1/es not_active Application Discontinuation
- 2007-09-25 PE PE2007001290A patent/PE20081225A1/es not_active Application Discontinuation
- 2007-09-26 TW TW096135785A patent/TWI452038B/zh active
- 2007-09-26 TW TW103104823A patent/TWI496775B/zh active
2009
- 2009-03-19 IL IL197717A patent/IL197717A/en active IP Right Grant
- 2009-04-16 NO NO20091488A patent/NO341858B1/no unknown
2010
- 2010-10-27 US US12/913,213 patent/US8394966B2/en active Active
2013
- 2013-02-12 US US13/764,807 patent/US8748625B2/en active Active
2014
- 2014-04-25 US US14/261,774 patent/US9309206B2/en active Active
2015
- 2015-01-09 JP JP2015003265A patent/JP6407733B2/ja active Active
- 2015-08-10 HK HK15107681.2A patent/HK1207070A1/xx unknown
2016
- 2016-03-14 US US15/068,792 patent/US10028939B2/en active Active
- 2016-04-22 LT LTPA2016012C patent/LTC2076501I2/lt unknown
2017
- 2017-05-29 JP JP2017106030A patent/JP6495375B2/ja active Active
- 2017-08-07 AR ARP170102217A patent/AR109300A2/es unknown
2018
- 2018-06-22 US US16/015,389 patent/US10300047B2/en active Active
2019
- 2019-03-06 JP JP2019040137A patent/JP2019104752A/ja not_active Withdrawn
- 2019-04-10 US US16/380,218 patent/US10959988B2/en not_active Expired - Fee Related
2020
- 2020-07-07 US US16/921,934 patent/US20200330440A1/en not_active Abandoned
2021
- 2021-02-24 US US17/183,342 patent/US20210330647A1/en not_active Abandoned
- 2021-05-31 JP JP2021090763A patent/JP7245868B2/ja active Active
- 2021-09-30 US US17/490,725 patent/US20220023268A1/en not_active Abandoned
2023
- 2023-03-13 JP JP2023038770A patent/JP2023078271A/ja active Pending

Also Published As

Publication number	Publication date
BRPI0717107A2 (pt)	2013-10-15
AU2007300542B2 (en)	2012-05-17
US20220023268A1 (en)	2022-01-27
AR109300A2 (es)	2018-11-14
SG10201609581TA (en)	2016-12-29
TWI452038B (zh)	2014-09-11
TW201420578A (zh)	2014-06-01
TW200823181A (en)	2008-06-01
PL2076501T3 (pl)	2016-06-30
ES2655338T3 (es)	2018-02-19
US10028939B2 (en)	2018-07-24
CA2663574A1 (en)	2008-04-03
PL2559689T3 (pl)	2018-04-30
SG185979A1 (en)	2012-12-28
HUE028503T2 (en)	2016-12-28
JP2023078271A (ja)	2023-06-06
US20200330440A1 (en)	2020-10-22
UA99600C2 (en)	2012-09-10
PT2076501E (pt)	2016-03-31
KR20090057457A (ko)	2009-06-05
CN102382075B (zh)	2015-10-28
EP2559689A1 (en)	2013-02-20
CL2007002743A1 (es)	2008-07-11
RU2009115649A (ru)	2010-11-10
US20180296538A1 (en)	2018-10-18
EP2076501A2 (en)	2009-07-08
PE20120768A1 (es)	2012-06-27
PE20151445A1 (es)	2015-09-28
JP6407733B2 (ja)	2018-10-17
CN104341371A (zh)	2015-02-11
JP2021130697A (ja)	2021-09-09
ES2563958T3 (es)	2016-03-16
NZ575795A (en)	2012-03-30
WO2008039431A3 (en)	2008-05-08
US20080171377A1 (en)	2008-07-17
US20110040100A1 (en)	2011-02-17
MY191209A (en)	2022-06-08
TWI496775B (zh)	2015-08-21
JP5714228B2 (ja)	2015-05-07
WO2008039431B1 (en)	2008-07-10
US20140235679A1 (en)	2014-08-21
JP2017160253A (ja)	2017-09-14
RU2474577C2 (ru)	2013-02-10
US7863456B2 (en)	2011-01-04
IL197717A0 (en)	2009-12-24
DK2076501T3 (da)	2016-02-29
US8394966B2 (en)	2013-03-12
US20130158081A1 (en)	2013-06-20
CN101541770A (zh)	2009-09-23
US20210330647A1 (en)	2021-10-28
EP2559689B1 (en)	2017-11-29
WO2008039431A2 (en)	2008-04-03
ZA200901949B (en)	2010-07-28
AU2007300542A1 (en)	2008-04-03
NO20091488L (no)	2009-06-17
NO341858B1 (no)	2018-02-12
EP2076501B1 (en)	2015-12-02
IL197717A (en)	2015-06-30
SI2076501T1 (sl)	2016-05-31
KR101430144B1 (ko)	2014-08-13
US10959988B2 (en)	2021-03-30
US20160193189A1 (en)	2016-07-07
CN102382075A (zh)	2012-03-21
JP2019104752A (ja)	2019-06-27
US10300047B2 (en)	2019-05-28
JP2010504340A (ja)	2010-02-12
MX344418B (es)	2016-12-15
US9309206B2 (en)	2016-04-12
MX2009003160A (es)	2009-04-06
AR062963A1 (es)	2008-12-17
US20190231754A1 (en)	2019-08-01
EP2076501B8 (en)	2019-11-13
JP6495375B2 (ja)	2019-04-03
CA2663574C (en)	2015-11-24
US8748625B2 (en)	2014-06-10
PE20081225A1 (es)	2008-09-04
JP7245868B2 (ja)	2023-03-24
JP2015110607A (ja)	2015-06-18
HK1207070A1 (en)	2016-01-22

Publication	Publication Date	Title
LTC2076501I2 (lt)	2017-10-10	3-[5-(2-fluorfenil)-[1,2,4]oksadiazol-3-il]benzenkarboksirūgšties kristalinės formos
IL195125A0 (en)	2011-08-01	1,3,4-oxadiazole derivatives as dgat1 inhibitors
ATE502033T1 (de)	2011-04-15	Herbizide isoxazolinverbindungen
DK2069338T3 (da)	2013-02-11	Insekticidale isoxazoliner
BRPI0914772A2 (pt)	2015-10-20	compostos heterocíclicos 1,2-dissubstituídos
JP2009524695A5 (lt)	2009-12-17
ZA200802488B (en)	2009-06-24	1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
BRPI0922642A2 (pt)	2016-01-05	"formas polimórficas de sal de cloridrato de 3-(1-{3[5-(1-metil-piperidin-4-ilmetóxi)-piridin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila e processos de fabricação do mesmo"
PL2035398T3 (pl)	2013-08-30	Immobilizowany 1,2-benzoizotiazolin-3-on
DK1989192T3 (da)	2009-11-02	1,3-dioxane carboxylsyrer
ZA201100422B (en)	2012-03-28	1,2-benzisothiazole compounds useful for combating animal pests
PT2722046T (pt)	2017-03-15	Forma cristalina 1 de 2-((r)-2-metilpirrolidina-2-yl)-1hbenzimidazol- 4-carboxamida
IL199239A0 (en)	2010-03-28	Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-
PL382346A1 (pl)	2008-11-10	Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
ECSP099344A (es)	2009-06-30	Modificaciones de cristal de la 3-(1h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-pirrol-2,5-diona
DK2222376T3 (da)	2011-07-25	3-(2,2,2-trimethylhydrazinium)propionatsalte til behandling af myokardieinfarkt
ATE503753T1 (de)	2011-04-15	Monolysinsalze von azolverbindungen
ZA200809554B (en)	2010-01-27	3-(pyridin-2-yl)-[1,2,4]-triazines for use as fungicides
FR2909465B1 (fr)	2009-02-13	Motoreducteur d'entrainement d'un store
ITVI20060291A1 (it)	2008-03-30	Macchina per separare l'uno dall'altro contenitori impilati
UA10325S (uk)	2005-06-15	Обгортка для цукерки «ведмедик»
ES1062094Y (es)	2006-08-01	Carrete desmontable.
SE0700083L (sv)	2008-01-05	Nya kristallina former 2
UA10548S (uk)	2005-07-15	Упакування для сигарет «classic»